S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

OncLive® On Air - A podcast by OncLive® On Air

Podcast artwork

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.